Education
About Us
Working with TipRanks
Follow Us
Bicara Therapeutics Inc. (BCAX)
NASDAQ:BCAX
RESEARCH TOOLSreports
BCAX Stock Chart & Stats
Day’s Range― - ―
52-Week Range$8.91 - $28.09
Previous CloseN/A
Volume80.52K
Average Volume (3M)614.84K
Market Cap
$852.20M
Enterprise Value$459.37M
Total Cash (Recent Filing)$0.00
Total Debt (Recent Filing)$0.00
Price to Earnings (P/E)―
Beta0.88
Next EarningsN/A
EPS EstimateN/A
Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)N/A
Shares Outstanding54,523,327
10 Day Avg. Volume539,322
30 Day Avg. Volume614,837
Financial Highlights & Ratios
PEG RatioN/A
Price to Book (P/B)N/A
Price to Sales (P/S)N/A
Price to Cash Flow (P/CF)N/A
P/FCF Ratio0.00
Enterprise Value/Market Cap0.54
Enterprise Value/RevenueN/A
Enterprise Value/Gross ProfitN/A
Enterprise Value/Ebitda-5.64
Forecast
1Y Price Target
$33.40Price Target Upside113.69% Upside
Rating ConsensusModerate Buy
Number of Analyst Covering6
---
Bicara Therapeutics Inc. News
---
Bulls Say, Bears Say
Bulls Say
Clinical TrialsThe combination of ficerafusp alfa and pembrolizumab has shown promising median progression-free survival results in HPV-negative patients.
Financial ResourcesBicara's current financial resources are expected to be sufficient to fund operations significantly beyond major upcoming data catalysts.
Product PerformanceThe combination of ficerafusp alfa and Keytruda showed a higher overall response rate and complete response rate in a specific patient group compared to previous treatments.
Bears Say
Financial PerformanceBicara reported a wider net loss than previously estimated due to greater-than-expected operating expenses.
Projected LossesThe projected full-year 2025 net loss is expected to be $1.73 per share, indicating continued financial challenges.
---
Ownership Overview
37.31% Insiders
6.24% Mutual Funds
0.01% Other Institutional Investors
52.86% Public Companies and
Individual Investors
BCAX FAQ
What was Bicara Therapeutics Inc.’s price range in the past 12 months?
Bicara Therapeutics Inc. lowest stock price was $8.91 and its highest was $28.09 in the past 12 months.
What is Bicara Therapeutics Inc.’s market cap?
Bicara Therapeutics Inc.’s market cap is $852.20M.
When is Bicara Therapeutics Inc.’s upcoming earnings report date?
The company’s upcoming earnings report date is not yet available.
How were Bicara Therapeutics Inc.’s earnings last quarter?
Bicara Therapeutics Inc. released its earnings results on Nov 12, 2024. The company reported -$1.6 earnings per share for the quarter, missing the consensus estimate of -$0.41 by -$1.19.
Is Bicara Therapeutics Inc. overvalued?
According to Wall Street analysts Bicara Therapeutics Inc.’s price is currently Undervalued.
Does Bicara Therapeutics Inc. pay dividends?
Bicara Therapeutics Inc. does not currently pay dividends.
What is Bicara Therapeutics Inc.’s EPS estimate?
Bicara Therapeutics Inc.’s EPS estimate for its next earnings report is not yet available.
How many shares outstanding does Bicara Therapeutics Inc. have?
Bicara Therapeutics Inc. has 54,523,327 shares outstanding.
What happened to Bicara Therapeutics Inc.’s price movement after its last earnings report?
Bicara Therapeutics Inc. reported an EPS of -$1.6 in its last earnings report, missing expectations of -$0.41. Following the earnings report the stock price went up 2.29%.
Which hedge fund is a major shareholder of Bicara Therapeutics Inc.?
Currently, no hedge funds are holding shares in BCAX
---
Bicara Therapeutics Inc. Stock Smart Score
Outperform
1
2
3
4
5
6
7
8
9
10
Analyst Consensus
Moderate Buy
Average Price Target:
$33.40 (113.69% Upside)
$33.40 (113.69% Upside)
Blogger Sentiment
Bullish
BCAX Sentiment 100%
Sector Average 70%
Sector Average 70%
Hedge Fund Trend
Increased
By 60.8K Shares
Last Quarter.
Last Quarter.
Crowd Wisdom
Positive
Last 7 Days ▼ 1.2%
Last 30 Days ▲ 2.4%
Last 30 Days ▲ 2.4%
News Sentiment
Neutral
Bullish news 50%
Bearish news 50%
Bearish news 50%
Company Description
Bicara Therapeutics Inc.
Bicara Therapeutics Inc., a clinical-stage biopharmaceutical company, develops bifunctional therapies for solid tumors. Its lead program is ficerafusp alfa, a bifunctional antibody that combines an epidermal growth factor receptor (EGFR) directed monoclonal antibody with a domain that binds to human transforming growth factor beta (TGF-b) for the treatment of solid tumors. The company was incorporated in 2018 and is based in Boston, Massachusetts. Bicara Therapeutics Inc. is a subsidiary of Biocon Limited.
---
BCAX Stock 12 Month Forecast
Average Price Target
$33.40
▲(113.69% Upside)
Technical Analysis
Arbutus Biopharma
―
Anavex Life Sciences
―
Cogent Biosciences
―
Dianthus Therapeutics
―
LENZ Therapeutics
―
Best Analysts Covering BCAX
1 Year
1 Year Success Rate
2/3 ratings generated profit
1 Year Average Return
-3.27%
reiterated a buy rating 20 days ago
Copying Robert Burns's trades and holding each position for 1 Year would result in 66.67% of your transactions generating a profit, with an average return of -3.27% per trade.
---